AB0773 Serum VEGF level may be have a role in the evaluation of treatment response and disease activity during TNFi therapy in patients with AxSpA

Autor: M. Gulec Yazir, E. Durak Ediboglu, G. Alp, H. Cinakli, İ. Kurut Aysin, E. Erpek, E. Otman Akat, S. Gucenmez, M. Ozmen, S. Ketenci, O. Bayindir, D. Solmaz, S. Akar

Publikováno v: Annals of the Rheumatic Diseases. 81:1512.2-1513

BackgroundPatient reported outcomes (BASDAI and BASFI) are used to evaluate disease activity in axial spondylarthritis (axSpA), however, apart from C-reactive protein (CRP) there are no widely used serum biomarkers to assess disease activity and trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd7dcdc5cd756032f6a937d4dab80a7f
https://doi.org/10.1136/annrheumdis-2022-eular.4305

AB0456 HYDROXYCHLOROQUINE MIGHT REDUCE MORTALITY IN PATIENTS WITH SYSTEMIC SCLEROSIS

Autor: S. Gucenmez, H. Cinakli, G. Alp, E. Durak Ediboglu, O. Bayindir, E. Otman Akat, Dilek Solmaz, G. Kabadayi, Servet Akar, I. Kurut Aysin, E. Erpek, Mustafa Özmen

Publikováno v: Annals of the Rheumatic Diseases. 80:1255.1-1255

Background:Systemic sclerosis (SSc) is a devastating disease that has a profound impact on life expectancy, reflected by a standardised mortality ratio of 3,5. There is still limited data regarding the predictive factors for mortality in patients wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1713aecae1b1b974c75e82d2dee735a2
https://doi.org/10.1136/annrheumdis-2021-eular.3685

AB0657 IMPROVEMENT IN DISEASE ACTIVITY IS ASSOCIATED WITH ENHANCEMENT IN THE QUALITY OF LIFE DURING TUMOUR NECROSIS ALPHA INHIBITOR TREATMENT; A PROSPECTIVE COHORT EXPERIENCE IN AXIAL SpA

Autor: G. Kabadayi, S. Gucenmez, Dilek Solmaz, O. Bayindir, E. Durak Ediboglu, E. Otman Akat, I. Kurut Aysin, Mustafa Özmen, H. Cinakli, Servet Akar, H. E. Oz

Publikováno v: Annals of the Rheumatic Diseases. 79:1623-1623

Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory condition affecting mainly axial skeleton. The disease usually starts in early adulthood and cause considerable impact on physical function, work ability and quality of life (QoL).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a6fce2c281b06353db528a562ac95f58
https://doi.org/10.1136/annrheumdis-2020-eular.4389

Non-steroidal anti-inflammatory drug use is determined by disease activity in axSpA and decreased by biologicals: a longitudinal analysis.

Autor: Durak Ediboğlu E; Department of Internal medicine, Division of rheumatology, Izmir Katip Celebi University Faculty of Medicine., Solmaz D; Department of Internal medicine, Division of rheumatology, Izmir Katip Celebi University Faculty of Medicine., Kabadayı G; Department of Internal medicine, Division of rheumatology, Izmir Katip Celebi University Faculty of Medicine., Gücenmez S; Department of Internal medicine, Division of rheumatology, Izmir Katip Celebi University Faculty of Medicine., Cinakli H; Department of Internal medicine, Division of rheumatology, Izmir Katip Celebi University Faculty of Medicine., Otman Akat E; Department of Internal medicine, Division of rheumatology, Izmir Katip Celebi University Faculty of Medicine., Özmen M; Department of Internal medicine, Division of rheumatology, Izmir Katip Celebi University Faculty of Medicine., Akar S; Department of Internal medicine, Division of rheumatology, Izmir Katip Celebi University Faculty of Medicine.

Publikováno v: ARP rheumatology [ARP Rheumatol] 2023 Oct-Dec; Vol. 2 (4), pp. 322-329.